Medistim Asa · OSL:MEDI
Medistim Asa — Q1 2016 Earnings Presentation
19 slides from Medistim Asa's earnings presentation, Apr 20, 2016
Slide 1: Medistim ASA First Quarter 2016
Medistim ASA First Quarter 2016 Kari E. Krogstad, President and CEO Thomas Jakobsen, CFO April 20th, 2016
Slide 2: Disclaimer
2 20.04.2016 Medistim ASA Q1 2016 Disclaimer The information included in this Presentation contains certain forward-looking statements that address activities, events or developments that Medistim ASA (“the Company”) expects, projects, believes or anticipates will or may occur in the future. These s
Slide 3: Table of contents
3 20.04.2016 Medistim ASA Q1 2016 Table of contents 1. Highlights first quarter 2. Financial statements 3. Business segments update 4. Implementing the strategy
Slide 4: 1. Highlights first quarter
MED (STIM ights first quarter ighl 1. H
Slide 5: Highlights first quarter 2016
5 20.04.2016 Medistim ASA Q1 2016 Highlights first quarter 2016 Q1 2016 QoQ • 13.1 % sales growth for the quarter o Sales of own products increased with 28.8 % to Revenue 13.1% MNOK 49.1 MNOK 65.5 (57.9) o US sales up 42.8 % to MNOK 22.9 3. party sales down by 17.1 % to MNOK 16.4 o EBIT 37.2 % MNOK
Slide 6: 2. Financial statements
2. Financial statements
Slide 7: Profit and loss Q1 2016
7 20.04.2016 Medistim ASA Q1 2016 Profit and loss Q1 2016 Profit & loss Q1 2016 Q1 2015 All numb ers in NOK 1000 Sales per Quarter (TNOK) Sales 65 500 57 907 80 000 Cost of goods sold 15 686 16 979 70 000 Salary and sosial expenses 22 397 18 864 60 000 Other operating expenses 11 044 9 640 50 000 To
Slide 8: Balance sheet - Assets
8 20.04.2016 Medistim ASA Q1 2016 Balance sheet - Assets Balance sheet 31.03.2016 31.12.2015 All numb ers in NOK 1000 250 000 Assets 200 000 Intangible assets 55 347 55 122 150 000 Fixed assets 14 707 14 158 Total intangible and fixed assets 70 054 69 280 100 000 Inventory 53 996 46 613 50 000 Custo
Slide 9: Balance sheet - Equity and liability
9 20.04.2016 Medistim ASA Q1 2016 Balance sheet - Equity and liability Balance sheet 31.03.2016 31.12.2015 250 000 All numbers in NOK 1000 200 000 Share capital 4 585 4 585 Premium fund 41 852 41 852 150 000 Other equity 119 269 109 727 100 000 Total equity 165 706 156 164 Total long term debt 6 721
Slide 10: 3. Business segments update
3. Business segments update
Slide 11: Flow probes and systems in units
11 20.04.2016 Medistim ASA Q1 2016 Flow probes and systems in units Flow probes in units (excl USA) Flow systems in units (VeriQ & MiraQ) 35 1 900 1 800 30 1 700 25 1 600 20 1 500 15 1 400 10 1 300 1 200 5 1 100 0 1 000 Q4 13 Q1 14 Q2 14 Q3 14 Q4 14 Q1 15 Q2 15 Q3 15 Q4 15 Q1 16 Q1 14 Q2 14 Q3 14 Q4
Slide 12: Imaging probes and systems in units
12 20.04.2016 Medistim ASA Q1 2016 Imaging probes and systems in units Imaging probes in units (incl USA) Imaging systems in units (VeriQC & MiraQ) 30 30 25 25 20 20 15 15 10 10 5 5 0 Q1 14 Q2 14 Q3 14 Q4 14 Q1 15 Q2 15 Q3 15 Q4 15 Q1 16 0 Q1 14 Q2 14 Q3 14 Q4 14 Q1 15 Q2 15 Q3 15 Q4 15 Q1 16 Imagin
Slide 13: Q1 revenue performance by region
13 20.04.2016 Medistim ASA Q1 2016 Q1 revenue performance by region Mill NOK Q1 '16 Q1 '15 Q/Q Europe 31,7 33,4 -5,0 % USA 23,0 16,1 42,8 % Asia & Jp 7,1 5,9 22,0 % ROW 3,7 2,6 41,8 % (MEA, CAN, SA) Total 65,5 57,9 13,1 % • In Europe, 3. party products declined by 17.1 % due to the loss of the Medtr
Slide 14: Q1 revenue performance by product
14 20.04.2016 Medistim ASA Q1 2016 Q1 revenue performance by product Mill NOK Q1 '16 Q1 '15 Q/Q Procedures (USA) 20,5 15,4 32,9 % Flow probes 17,2 13,8 24,5 % Flow systems (VeriQ & MiraQ) 4,3 2,7 59,9 % Imaging systems (VeriQ C & MiraQ) 5,9 4,6 26,6 % Imaging probes 0,8 0,9 -7,7 % 3rd party 16,4 19,
Slide 15: 4. Implementing the strategy
4. Implementing the strategy
Slide 16: Growth opportunities – in underdeveloped markets
16 20.04.2016 Medistim ASA Q1 2016 Growth opportunities – in underdeveloped markets Emerging, 1. Strengthen our position as market leader by high-growth establishing combined TTFM & Imaging as the new markets standard of care through (BRICs) o Early adopter KOL support o Easier conversion to imaging
Slide 17: High performance US sales organization
17 20.04.2016 Medistim ASA Q1 2016 45000 40000 35000 High performance US sales organization 30000 25000 20000 2010 2011 2012 2013 2014 2015 Number of procedures per year RESULTS 2015 # of Procedures per Consecutive Quarter • Revenues up by 42.8 % in NOK 11 500 • 24.6 % growth in USD 10 500 • Number
Slide 18: The MiraQ system family launched in the USA
18 20.04.2016 Medistim ASA Q1 2016 The MiraQ system family launched in the USA • 23-25. January 2016: MiraQ Cardiac, Vascular and Ultimate launched at the Society of Thoracic Surgery meeting in Phoenix, Az • Sales team fully trained • Over half of the pipeline deals are MiraQ • Complete vascular pro
Slide 19: Seeing is believing
19 20.04.2016 Medistim ASA Q1 2016 Seeing is believing